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Abstract The numbers and proportions of elderly are increasing rapidly in developing countries, where prevalence
of dementia is often high. Providing cost-effective services
for dementia sufferers and their caregivers in these resourcepoor regions poses numerous challenges; developing resources for diagnosis must be the first step. Capacity building for
diagnosis involves training and education of healthcare providers, as well as the general public, development of infrastructure, and resolution of economic and ethical issues.
Recent progress in some low-to-middle-income countries
(LMICs) provides evidence that partnerships between
wealthy and resource-poor countries, and between developing countries, can improve diagnostic capabilities.
Without the involvement of the mental health community of developed countries in such capacity-building
programs, dementia in the developing world is a disaster waiting to happen.
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Introduction
Dementia disrupts normal functioning of affected individuals and their families, imposing significant social and economic burdens. The problem is especially severe in low-tomiddle-income countries (LMICs), where dementia is the
most important independent contributor to disability in the
elderly [1] and resources to diagnose and treat dementia are
limited. By the mid-21st century, 78 % of the world’s elderly
population will reside in LMICs, with expected concomitant
increases in dementia cases [2]. Prevalence of dementia is
relatively low in some LMICs, but other regions have a
prevalence similar to or higher than that in developed
countries [3]. For example, Latin America and the Caribbean (LAC) have the world's highest prevalence of dementia
(8.5 % in subjects ≥60 years vs. 6.4 % in the U.S.) [3–5].
It is in resource-poor regions with a high prevalence of
dementia that cost-effective health care targeted at vulnerable populations is most needed. However, dementia care is
problematic, even in high-income countries, many patients
with dementia remain undiagnosed and, therefore, untreated
[6, 7•]. The governments of LMICs and international healthcare agencies have tended to disregard chronic conditions of
the elderly, due to more immediate and widespread problems of malnutrition and communicable diseases. However,
the World Health Organization (WHO) recently released
guidelines for increasing treatment of dementia in LMICs
[8] and urged governments to consider dementia as a public
health priority [9••]. Developing effective approaches for
diagnosis is the first step toward providing adequate services
for dementia sufferers and their caregivers. In this article, I
review strategies used to diagnose dementia in resourcepoor regions, discuss the particular challenges associated
with those assessments, describe some recent strategies for
developing and improving diagnosis in poor countries, and
consider how diagnosis of dementia might be improved in
the future.

512

Curr Neurol Neurosci Rep (2012) 12:511–519

Prevalence of Dementia in the Developing World

Diagnosing Dementia

There are many estimates of age-specific or age-and-genderspecific dementia prevalence in the developed world, based
on epidemiological studies. However, WHO identified only
64 such studies in 14 developing countries [9••]. Where
such data are not available, estimates have been derived
from a Delphi consensus of experts [10]. Furthermore, the
age-specific and age-and-gender-specific estimates for developing countries are often compared with estimates for
developed countries, despite different population structures.
Therefore, estimates of the prevalence of dementia in the
developing world should be viewed with caution.
Most estimates of the prevalence of dementia in people
older than 60 years fall between 5 % and 7 % [3]. Variation
in actual prevalence—as opposed to variation in detected
dementia—is influenced by a number of factors. For example, low prevalence in sub-Saharan Africa (2.1 %) might be
due to selective mortality of people younger than 60 years
[11]. High prevalence in LAC (8.5 %) might be related to
the high occurrence or confluence of genetic and/or environmental risk factors [5]. For example, increased mobility
of individuals and families has spread genetic isolates with
an extremely high prevalence of dementia, such as those
with early-onset Alzheimer´s disease in Medellin, Colombia
[12] and Huntington’s disease in Maracaibo, Venezuela
[13]. The fact that expression of the disease occurs after
reproductive age might also contribute to its spread. Finally,
in consanguineous marriages, which are relatively common
in some resource-poor areas, dementia in either or both
parents increases the risk of having children who will be
affected in the future [14].
Population demography and other factors play an important role in determining the prevalence of dementia. Both
prevalence and incidence of dementia increase exponentially with age, making age the main risk factor for the disease
[9••, 15]. The number of people at risk of dementia in the
developing world will increase rapidly during the next
50 years, because the population and proportion will grow
faster for the elderly (≥60 years) than for other age
groups [16]. In India, for example, the population of
individuals ≥80 years will increase from 5.4 million in
2001 to 32 million in 2051 [17]. In addition to aging
populations, gradual improvements in health care in
developing countries are probably increasing the time
that affected individuals survive with dementia [18].
Other factors that might affect the incidence of certain
types of dementia—for example, cardiovascular risk
factors, such as obesity, metabolic syndrome, and sedentary life—are also escalating much more rapidly in
developing than in developed countries [19–22]. In consequence, the dementia burden in the developing world
is expected to increase significantly.

Diagnosis of dementia and accurate determination of subtype early in the course of the disease are crucial for optimal
clinical care and management. Traditionally, dementia has
been defined as a global impairment of intellectual function
that requires anatomopathological examination to provide
accurate diagnosis and differentiation among subtypes
[23–25]. However, research involving biomarkers and neurogenetics now allows identification of patients years, perhaps decades, before the diagnosis of dementia is made,
such as in presymptomatic Alzheimer´s disease [26].
The National Institute on Aging and the Alzheimer´s
Association recently released revised criteria for all-cause
dementia [27], which include neuropsychiatric or cognitive
symptoms, rather than just cognitive deficits, that interfere
with daily functioning, represent a decline from previous
levels, and are not explained by delirium or major psychiatric disorders. A new category was added, primarily
intended for research purposes: dementia due to possible
or probable Alzheimer´s disease with evidence of the
Alzheimer pathology. The new category requires that a
subject meeting the clinical criteria for Alzheimer´s disease
also exhibits changes in biomarkers related to the current
understanding of the pathophysiology [28]. The revised criteria for Alzheimer´s disease include a predementia stage, in
which a subject is asymptomatic but shows evidence of the
underlying brain pathology specific for Alzheimer´s disease.
These new criteria will be of limited use in the developing
world, because the ability to detect relevant biomarkers and
pathologies is low, due to the high cost of testing and the lack
of infrastructure.
To establish a diagnosis of dementia, an evaluation focuses on, as a clinical syndrome, cognitive performance and
behavior of the subject, changes in the activities of daily
living, and exclusion of other possible causes. Diagnosing
dementia, particularly in the early stages, is neither simple
nor straightforward. The clinical interview is considered to
be an art. The first step is usually to elicit a complete history
of signs and symptoms, recalled and recounted by the patient and/or an informant. A highly skilled interviewer structures the interaction as a conversation, establishing rapport
and confidence and enabling the patient to fully disclose
even embarrassing details. Neuropsychological, neuroimaging, and other diagnostic tests are used to distinguish pathological changes within the brain that characterize different
dementia syndromes. Interpretation of the clinical interview
and test results requires training and often varies among
individuals making the judgment.
The clinician uses as many tools as possible—clinical
examination, laboratory tests, neuroimaging, genetic
testing—to determine the underlying pathology or type
of dementia and establish the best therapeutic course as
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early as possible. However, the diagnostic profiles of
different dementia subtypes are not 100 % distinct, and
the correlation between clinical and pathological diagnoses is not perfect, even when based on the most
advanced tools [18]. Furthermore, diagnostic profiles
exhibit a great deal of heterogeneity, even among
patients who share the same pathology, and some are
frankly atypical [29]. Because of these challenges, accurate diagnosis requires an experienced clinician, supported by an array of complex tools [7•, 30]

Obstacles to Diagnosis of Dementia in Poor Populations
Many factors contribute to limited diagnosis of dementia in
resource-poor areas (Table 1). Three major obstacles are (1)
low health literacy, (2) limited access to health care, and (3)
the stigma associated with dementia. The extent of health
illiteracy, including ignorance of the connection between
behavioral, cognitive, or physical signs and the disease
[31], is difficult to estimate but very important, as is lack
of awareness that appropriate care/treatment is available
[32]. Surprisingly, such ignorance often exists in educated
individuals and even in healthcare professionals [33]. Lack
of knowledge in healthcare workers particularly affects their
ability to recognize early signs of dementia. Many people in
developing countries believe that the characteristic signs of
dementia are part of normal aging or a nonpathological
deviation [34]. Improving health literacy is the goal of
health promotion and education programs, which are often
given low priority in resource-poor settings. On the other
hand, the impact of a lack of specific or scientific knowledge should not be overestimated. Cultures in developing
Table 1 Likely causes of limited dementia diagnoses in resource-poor
areas
- Initial symptoms are subtle and fluctuating
- Inability to recognize cognitive, behavioral, or functional impairment
as a consequence of dementing illness
- Accommodation, denial, and rationalization of symptoms as due to
aging and adverse circumstances
- High tolerance for health problems in elderly individuals
- Person with early symptoms does not feel the need to seek treatment
- Relatives do not believe symptoms are treatable
- Demoralization regarding medical assistance, due to ignorance of
available treatments
- Do not know where to go for diagnosis
- Family is afraid of psychiatric stigma (demented is often equated to
being crazy)
- Physician underemphasizes the importance of symptoms
- Perception that physicians will miss the diagnosis and will make the
family waste time and money in apparently unnecessary tests
- Costs of diagnosis in terms of effort, time, economic costs
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countries often have knowledge about signs, based on common sense and traditional practices, that informs choices
about care/treatment [35].
Limited access to health care is a universal problem in
diagnosing dementia in LMICs. Geriatric care is generally
minimal, and there is virtually no concept of continuing care
for aging adults [36–38]. In addition to inadequate numbers
of personnel and facilities, the costs involved in accessing
services and long waits for appointments are common barriers. If an elderly person has to travel a long distance to
receive a diagnosis and treatment, he or she must weigh the
likelihood of improvement against the difficulties and costs
of travel [39]. Travel where public transportation is not
adequate for people with physical disabilities can be a
limitation. Additionally, the patient and his or her caretakers might fear that there is no effective treatment,
that treatment will require expensive drugs, or that the
patient might have to stay at an asylum or hospice. Any
or all of these factors might prevent a potential patient
or caregiver from seeking medical attention, particularly
in the case of a chronic condition that has established
slowly, such as dementia.
The social stigma associated with mental health problems
is a barrier to diagnosing dementia [40–42]. When dementia
is medicalized and acquires the label of a disease, the social
value of the individual and his or her family often suffers
[11, 35]. Even when it is not labeled as a disease, signs of
dementia are a fairly common condition in many resourcepoor regions, and most people have a negative expectation
of recovery [11]. Behavioral changes associated with dementia sometimes elicit abuse, neglect, or loss of family
members’ respect [40]. Even healthcare workers are sometimes guilty of a negative attitude toward dementia patients
[41–43].
In addition to health illiteracy, poor access to healthcare,
and social stigma, diagnosing dementia in poor populations
remains problematic for a number of reasons. Although the
clinical features and complications of dementia have been
relatively well defined [44], expression of behavioral and
cognitive signs and symptoms might be modulated by socioeconomic conditions [41], possibly accounting for some
of the phenotypic heterogeneity of various subtypes. Longterm studies are needed of the effects of lifestyles in developing countries on each of the dementia subtypes [45].
Although some genetic and environmental modifiers have
been identified [46–48], it is still not possible to predict the
likely course of the illness, even when dominant mutations
are present [45]. The effects of concomitant comorbidities,
such as hypertension and diabetes, are not clearly understood, particularly when untreated or uncontrolled for most
of the life of the patient [49].
Practical approaches to overcoming some obstacles to
diagnosis of dementia have been addressed in the context
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of minority populations [50•] (Table 2). There are other
obstacles, particularly to early diagnosis of dementia, that
are beyond the scope of this article [51]. However, it is
important to recognize that economic crises, epidemics,
famine, war, displacement, and natural disasters have devastating effects on populations in resource-poor countries,
which relegate the health of elderly individuals to low
priority [52, 53]. Barriers to improvement of dementia diagnosis and care are similar to those confronting mental
health services [54]. Overcoming those barriers will require
changes in politics, leadership, planning, advocacy, and
participation [55].
Inarguably, it is crucial to reliably diagnose individuals with dementia in order to carry out clinical trials
for treatments, to advance genetic studies, and to proceed with epidemiological studies that allow the establishment of specific risk factors. However, because there
is no definite marker for the disease (except when
relatively rare dominant genetic alterations are present
and consistent with symptomatology), population screening and preclinical diagnosis in general populations are
not yet cost effective and have not been implemented
even in wealthy countries. Even screening for the
ApoE-4 allele, the strongest risk factor for Alzheimer´s
disease in most populations, is not generally recommended because of prognostic uncertainty [56]. In contrast,
screening populations at high risk for dementia (e.g.,
elderly individuals with a medical history of risk factors
for dementia) might be justifiable, but systematic recommendations have not been developed [57]. Nevertheless, the benefits of early diagnosis, coupled with proper
care and caregiver support, outweigh the costs of diagnosis in developing countries [7•]. Although the only
specific treatment for dementia, cholinesterase inhibitors
and/or memantine, is available to a relatively small number
of patients, primarily in wealthy countries [58], therapeutic
interventions are currently being tested. Now is the time to
prepare for their availability.
Table 2 Options for and
challenges to confronting critical
issues in the diagnosis of
dementia among minorities that
are applicable to resource-poor
regions

Human Resource Capacity for Diagnosing Dementia
in LMICs
While the number of specialty centers for dementia care has
grown considerably in wealthier countries, apart from a few
evolving areas [59–61], facilities for diagnosis and treatment of dementia are scarce in LMICs [62].
There is also a paucity of specialists devoted to health
care of the elderly and to brain and mental health disorders
[63–68]. Neuropsychologists and biometricians who are
competent to administer standardized tests to local populations and interpret the results are rare, so normative values
that can be appropriately applied by clinicians in diagnosing
dementia are even rarer [51, 69]. The Kyoto Declaration of
Alzheimer´s Disease International (ADI), on the basis of the
recommendations of WHO 2001 [70], recommended integrating dementia outreach into existing primary health care,
and WHO developed evidence-based guidelines for management of dementia by nonspecialists in LMICs [8]. Nevertheless, most primary care physicians and even many
specialists in developing countries do not receive suitable
training to diagnose dementia and its subtypes [40], despite
efforts to remedy this situation during the past few
years [71].
Building capacity to recognize and accurately diagnose
dementia in LMICs, by training local healthcare personnel,
is necessary to expand access to and improve mental health
care [7•, 64]. To date, most initiatives for training healthcare
workers in dementia diagnosis have depended largely on
face-to-face interactions [72, 73], but the role of distance
and Web- or mobile-telephone-based training is increasing
[74–76]. However, none of the Web-based programs appear
to offer training in different languages or to include specific
information on assessment of individuals with low levels of
education. Capacity-building efforts should also aim to
improve referral pathways and promote multidisciplinary
care of dementia patients, which will require training of
nurses, social workers, and other healthcare personnel,

Issues

Options

Challenges

Need culture-unbiased
instruments

Adapt existing tests

Comparability

Develop new instruments

Undetermined value of
informant data

Identify key informant
Home-based interview

Assessment of daily
functioning

Skilled clinician

Alteration of psychometric properties
Need local normative values
Stigma
Oversimplification of complex social
relationships and environments
Time consuming

Interpretation of conflicting
information

Home-based interview
Multidisciplinary
consensus on diagnosis
Algorithm diagnosis

Specific to setting
Experienced clinical judgment
Intimate knowledge of culture
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in addition to specialists, such as geriatricians, neurologists, and psychiatrists.
Continued medical education in much of the developing world is currently subsidized by pharmaceutical
industries [77], without strict regulations on content or
selection of presenters. It is not surprising that many
educational and dissemination programs on dementia are
biased toward pharmacological approaches and downplay nonpharmacological strategies for managing behavioral symptoms [78]. Improvement and expansion of
those programs to include dementia require input by
both large international agencies and academia. Little
is likely to be accomplished without their recognition
of dementia as a public health problem in poor populations, with emphasis on prevention of risk factors, early
diagnosis, and improved caregiving.

Economic Issues Affecting Diagnosis of Dementia
in LMIC
Economic issues are critical to the control and management of dementia in LMICs [79]. Economic issues also
drive the perceived need for early diagnosis of dementia
and differentiation of subtypes [7•]. To develop appropriate and effective policies, resource-poor countries require
information about the overall prevalence and clinical
burden of dementia in their populations, as well as
cost–benefit analysis of accurate diagnosis and improved
health care.
The human capital contributed by the most able elders,
particularly in early stages of the aging process (55–
70 years), is critically needed in developing countries; their
experience contributes significantly to both economic productivity and family stability [80]. One way to visualize the
economic costs of dementia is to consider the potential years
of healthy life lost to disability (loss of function) and to
premature death, through the concept of disability-adjusted
life years (DALYs) [81]. Economic impact of disease also
can be assessed by quality-adjusted life year (QALY), which
combines duration and quality of life [82]. Since most of the
dementia cases diagnosed in the developing world are of
moderate to advanced severity, the price paid by society,
either in DALYs or QALYs, is very high.
Cost-comparison analyses use the costs of diagnosis and
of pharmacological and psychosocial interventions and other relevant costs to estimate the economic benefits of early
diagnosis and early interventions [58, 83, 84]. A lack of
mortality and natural history data make such calculations
difficult for LMICs. Although not entirely projectable to
resource-poor areas, a few general conclusions have been
drawn from studies of developed countries [83–85]. First,
the net benefits of early identification and intervention
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exceed costs, with significant savings expected. Second,
the earlier the diagnosis and intervention, the greater the
net benefits. Finally, caregiver interventions at earlier stages
have beneficial economic effects. However, these analyses
were not based on direct observations or randomized controlled trials, and no such analyses have been made for
countries in the developing world.

Ethical Issues Related to Diagnosis of Dementia
in LMIC
Perceptions of the nature of disease, what social scientists
call social representations of disease [86], vary widely
among different populations and ethnic groups, resulting
in the need to adapt educational and counseling programs
related to dementia [42]. Low levels of education and health
literacy, poor access to health care, and the fact that many
elderly subjects live within extended families pose ethical
dilemmas that need to be discussed with healthcare workers
before an early detection program is implemented in a
resource-poor community.
The key ethical principles guiding the process of
disclosure of diagnosis at early stages in the disease
are beneficence, respect for the autonomy of patients,
and justice for patients [87, 88]. In other words, the
clinician weighs the possible benefits and harm of disclosure, and this process is related to perceptions about
the ability of the patient to understand and/or retain
information, the potential psychological impact, and
beliefs about the efficacy of treatments [89]. Respecting
the patient’s autonomy is based on the notion that every
individual has a right to control his/her life, as stated in
Black´s Alzheimer Bill of Rights [90]. The principle of
justice involves hearing the voice of patients, acknowledging their vulnerabilities, giving them a chance to
decide important issues while decision making is still
possible, and not marginalizing them.
Unfortunately, no one has studied preferences or the
impact of diagnostic disclosure in developing countries
among patients, caregivers, and health professionals. It
could be difficult to persuade family members that some
signs and symptoms in their elderly relatives are due to
a disease of the brain, and not just to the process of
aging. The belief that an affected individual will become seriously dependent can have disastrous effects,
including marital breakdown, suicide by the patient, and
social stigma for family members [11, 91]. Attitudes
toward dementia diagnoses are often based on religious
or spiritual beliefs [92]. These issues are even more
sensitive when a dominant gene is implicated in the
dementia, possibly resulting in discrimination and/or
exclusion [93]. Until research on the impact of disclosure is
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conducted in developing countries, the decision to disclose a diagnosis must depend on the probable impact
on a particular patient: “If a patient is likely to benefit,
he or she should be told, but if benefit is not likely, or
if disclosure is instead apt to bring about an adverse
reaction, the disclosure is not advised” [94].

The Role of International Partnerships in Improving
Diagnosis of Dementia in Resource-Poor Countries
Partnerships between wealthy countries and LMICs
(North/South partnerships) and partnerships between
LMICs that have expertise in dementia and adjacent
countries with no such expertise (South/South partnerships) are two strategies for improving diagnosis of
dementia in resource-poor populations. However, those
strategies have been implemented parsimoniously, and
with few exceptions, large international funding organizations have shown little interest in partnering with
LMICs to build capacity for dementia diagnosis.
Some genuine partnerships encompassing research
and capacity building for delivery of services in developing countries have been extremely successful, not
only in terms of scientific productivity, but also in the
creation of services and dementia care options [95–97].
The research components of these partnerships have
primarily been funded through governments and charitable organizations of high-income countries (North/
South partnerships). Several agencies, including the
Fogarty International Center of the NIH, have developed
a program called “Brain Disorders in the Developing
World: Research Across the Lifespan.” The program
includes research and capacity building and has funded
several initiatives devoted to dementia.
Only 8 % of mental health projects to date involved
collaboration between LMICs, as compared with 30 % that
involved collaboration with high-income countries [98].
Capacity building has less often been included in South/
South partnerships, which have generally been supported by
a variety of sources, including individual donors and charitable organizations. In most cases, the resulting programs
have been expected to be self-sustaining after the development of services. However, the potential of South/South
collaborations is beginning to emerge as a significant mechanism for empowering countries in resource-poor areas.
Such partnerships can provide alternative sources of financial and technical assistance [99], like the collaboration in
which Indian universities have provided virtual classes for
medical staff and online consultations in Africa [99]. However, funding allocated for research on mental and neurological conditions in LMICs is vastly insufficient, and
lobbying of international organizations by coalitions of
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LMICs might be needed to gain external support for
South/South partnerships.
The main goals of international partnerships should
be to accelerate diagnosis and provision of services for
dementia in resource-poor regions, empowering locals
through training programs that include dementia as one
component. The partnerships should develop connections with the governments of LMICs and should educate the general population about dementia as a public
health problem.

Conclusions
As infant and childhood mortality rates decline and life
expectancies lengthen in LMICs, increases in both total
population size and the proportion of elderly individuals
will make dementia an increasingly severe burden on
healthcare resources. Prevalence of dementia is already
high in some developing countries. In Africa, India, and
Bangladesh, where prevalence of dementia is currently
low, rapidly increasing populations of elderly and increasing prevalence of risk factors, such as HIV-related
dementia and traumatic brain injury, foretell a rise in
dementia patients that is a disaster waiting to happen.
Local governments are unlikely to switch their attention
from ongoing problems of malnutrition and communicable disorders to an “incurable” disease like dementia.
Furthermore, prevalence of many preventable chronic
diseases, such as diabetes and cardiovascular disease, is
increasing as LMICs adopt westernized lifestyles, further
increasing pressure on limited healthcare resources.
There are currently no preventive measures or cures for
dementia. Even if promising immunological approaches,
gene therapy, or other strategies turn out to be safe and
effective, they are likely to be expensive. Therefore, better
management is the most appropriate approach for dealing
with dementia in the developing world. However, it appears
unlikely that funding agencies will develop initiatives to
improve diagnosis of dementia in developing countries in
the near future. Thus, it is vital for the international healthcare community to take action now to strengthen existing
initiatives, develop North/South and South/South partnerships, and build capacity for dementia diagnosis in resourcepoor populations.
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